Phase I Clinical Study of the Feasibility of Pretargeted Radioimmunotherapy of an Anti-CEA Bispecific Antibody and Lu-177-labeled Peptide in Patients With Advanced Colorectal Cancer.

Trial Profile

Phase I Clinical Study of the Feasibility of Pretargeted Radioimmunotherapy of an Anti-CEA Bispecific Antibody and Lu-177-labeled Peptide in Patients With Advanced Colorectal Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2012

At a glance

  • Drugs Lutetium-177-IMP 288; TF 2
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jun 2012 Immunomedics releases updated results for this trial.
    • 02 Apr 2012 Results were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in 2012.
    • 16 Mar 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top